Related Experiment Videos
Docetaxel and interstitial pulmonary injury
M Merad1, A Le Cesne, P Baldeyrou
1Department of Medicine, Institut Gustave Roussy, Villejuif, France.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Bacteroidetes promote hepatocellular carcinoma progression and resistance to immunotherapy.
bioRxiv : the preprint server for biology·2025
Radiation-associated angiosarcoma of the breast: consider chemotherapy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Annals of oncology : official journal of the European Society for Medical Oncology·2026